Synergy Research Group

Clinovo expands CRO program’s global reach

Friday, November 6, 2015

Sunnyvale, Calif.-based Clinovo has moved forward with global expansion of its CRO Partner Program utilizing ClinCapture, the next-generation electronic data capture (EDC) software for CROs. Ten new CRO partners have been added in the United States, Russia, Spain, Mexico, India, and Japan. [Read More]

ClinTec International expands into South Africa

Monday, June 15, 2015

Global CRO ClinTec International has expanded with a Regional Hub Office for Sub-Saharan Africa in Johannesburg, South Africa. Aligning with new client partnerships, the office will support region wide clinical research services including a significant new clinical FSP assignment with a global biotechnology major where ClinTec is the sole FSP partner for South Africa. 

[Read More]

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Thursday, October 16, 2014

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company’s statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

[Read More]

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

[Read More]

Clinical Trial Activity in Russia Dipped in 2009

Friday, March 5, 2010

According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.

[Read More]

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

[Read More]